Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Waldenstrom Macroglobulinemia × Thalidomide × Clear all

Phase

Phase 2 5 Phase 4 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Waldenstrom Macroglobulinemia 1 Stomach Neoplasms 1 Neoplasms, Second Primary 1 Neoplasms 1 NSCLC 1 Multiple Myeloma 1 Lymphoma, Mantle-Cell 1 Immunoglobulin Light-chain Amyloidosis 1

Interventions

zanubrutinib 2 talquetamab 1 ibrutinib 1 Thiotepa 1 Thalidomide 1 Sirolimus 1 Rituximab 1 Radiotherapy 1 Prednisone 1 Filgrastim 1 Everolimus 1 Cyclophosphamide 1 Bortezomib 1 Antilymphocyte Serum 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02844309 2026-02-11

BDH-WM02

Institute of Hematology & Blood Diseases Hospital, China

Phase 4 Completed

Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡